In utero copper treatment for Menkes disease associated with a severe ATP7A mutation
详细信息 查看全文
- 作者：Marie Reine Haddad ; Charles J. Macri ; Courtney S. Holmes ; David S. Goldstein ; Beryl E. Jacobson ; Jose A. Centeno ; Edwina J. Popek ; Willam A. Gahl ; Stephen G. Kaler
- 关键词：Copper ; ATP7A ; Fetal therapy ; Menkes disease ; mRNA splicing
- 刊名：Molecular Genetics and Metabolism
- 出版年：2012
- 出版时间：September-October, 2012
- 年：2012
- 卷：107
- 期：1-2
- 页码：222-228
- 全文大小：426 K
文摘
Menkes disease is a lethal X-linked recessive neurodegenerative disorder of copper transport caused by mutations in ATP7A, which encodes a copper-transporting ATPase. Early postnatal treatment with copper injections often improves clinical outcomes in affected infants. While Menkes disease newborns appear normal neurologically, analyses of fetal tissues including placenta indicate abnormal copper distribution and suggest a prenatal onset of the metal transport defect. In an affected fetus whose parents found termination unacceptable and who understood the associated risks, we began in utero copper histidine treatment at 31.5 weeks gestational age. Copper histidine (900 ¦Ìg per dose) was administered directly to the fetus by intramuscular injection (fetal quadriceps or gluteus) under ultrasound guidance. Percutaneous umbilical blood sampling enabled serial measurement of fetal copper and ceruloplasmin levels that were used to guide therapy over a four-week period. Fetal copper levels rose from 17 ¦Ìg/dL prior to treatment to 45 ¦Ìg/dL, and ceruloplasmin levels from 39 mg/L to 122 mg/L. After pulmonary maturity was confirmed biochemically, the baby was delivered at 35.5 weeks and daily copper histidine therapy (250 ¦Ìg sc b.i.d.) was begun. Despite this very early intervention with copper, the infant showed hypotonia, developmental delay, and electroencephalographic abnormalities and died of respiratory failure at 5.5 months of age. The patient's ATP7A mutation (Q724H), which severely disrupted mRNA splicing, resulted in complete absence of ATP7A protein on Western blots. These investigations suggest that prenatally initiated copper replacement is inadequate to correct Menkes disease caused by severe loss-of-function mutations, and that postnatal ATP7A gene addition represents a rational approach in such circumstances.